Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | DTYMK | P23919 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5824222 | 0.90 | POLB (0.44) | POLBGPR119PKLROPRD1OPRK1 | |
| SCHEMBL4013541 | 0.88 | POLB (0.56) | POLBGPR119PKLROPRD1OPRK1 | |
| SCHEMBL3436213 | 0.88 | POLB (0.50) | POLBGPR119OPRD1OPRK1DTYMK | |
| SCHEMBL3787005 | 0.88 | POLB (0.50) | POLBGPR119PKLROPRD1OPRK1 | |
| SCHEMBL5479635 | 0.86 | POLB (0.51) | POLBGPR119OPRD1OPRK1DTYMK | |
| SCHEMBL12701930 | 0.86 | POLB (0.48) | POLBGPR119OPRD1OPRK1DTYMK | |
| SCHEMBL5467346 | 0.86 | PKLR (0.52) | POLBGPR119PKLROPRD1OPRK1 | |
| SCHEMBL22792894 | 0.83 | POLB (0.48) | POLBGPR119OPRD1OPRK1DTYMK | |
| SCHEMBL3555626 | 0.83 | POLB (0.48) | POLBGPR119OPRD1OPRK1DTYMK | |
| SCHEMBL3662831 | 0.83 | POLB (0.48) | POLBGPR119OPRD1OPRK1DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467995-B1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | MERCK SHARP & DOHME LTD. (GB) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | POLB 1729/4885GPR119 263/4885PKLR 3460/4885 |
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | OPRL1, HVCN1, TRPV1 | POLB 4785/4885GPR119 1500/4885PKLR 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.